First‐In‐Human Dose Finding Study of Venadaparib (<scp>IDX</scp>‐1197), a Potent and Selective <scp>PARP</scp> Inhibitor, in Patients With Advanced Solid Tumors
Further studies are warranted to explore efficacy and safety of venadaparib in other tumor types and in combination with various agents, as well as to explore relevant biomarkers. (ClinicalTrials.gov ID: NCT03317743).
Authors
- Myongjae Lee (ORCID: https://orcid.org/0000-0002-0306-6908)
- Kyun‐Seop Bae (ORCID: https://orcid.org/0000-0001-7399-5879)
- Eun‐Jihn Roh
- Jeongsook Bang
- Sung‐Bae Kim
- Kyoung Soo Ha (ORCID: https://orcid.org/0000-0002-1216-7516)
- Chan‐Young Ock (ORCID: https://orcid.org/0000-0002-6755-9728)
- Jong‐Ha Lim (ORCID: https://orcid.org/0000-0003-0519-4951)
- Jae‐Lyun Lee (ORCID: https://orcid.org/0000-0002-9420-7162)
- Won Sik Lee (ORCID: https://orcid.org/0000-0001-9502-2429)
- Yong‐Man Kim (ORCID: https://orcid.org/0000-0003-3391-4426)
- Min Hong
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Ildong (South Korea) (KR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70576
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09